Revolution Medicines, Inc. (RVMD) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $158.96: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: Below-average business quality.
Revolution Medicines is a clinical-stage precision oncology company developing RAS(ON) inhibitors. Lead asset daraxonrasib is in multiple Phase 3 trials for pancreatic cancer and NSCLC, with a key readout from RASolute 302 expected in H1 2026. The pipeline also includes... Read more
Sell if holding. Engine safety override at $158.96: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.6/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Revolution Medicines, Inc.
About Revolution Medicines, Inc.
Revolution Medicines ended 2025 with $2.0 billion in cash, cash equivalents, and marketable securities but an accumulated deficit of $2.9 billion after net losses of $1.1 billion in 2025, $600.1 million in 2024, and $436.4 million in 2023 — the largest annual loss since the company's October 2014 inception. The company has no approved products and has never generated revenue from product sales. Four compounds are in active clinical development: daraxonrasib (RMC-6236, multi-selective RAS(ON) Inhibitor), zoldonrasib (RMC-9805, G12D-selective), elironrasib (RMC-6291, G12C-selective), and RMC-5127 (G12V-selective).
Revolution Medicines' financial model is research-stage: operations are funded through public equity offerings ($2.1 billion raised in underwritten offerings since inception) and non-product revenue agreements. In June 2025, the company received $250.0 million in gross proceeds from a Royalty Purchase Agreement with Royalty Pharma, which grants Royalty Pharma a security interest in certain daraxonrasib-related assets and imposes diligence covenants tied to specific clinical and regulatory milestones. Five Phase 3 registrational trials are active: RASolute 302 (daraxonrasib vs. chemotherapy in second-line PDAC, readout expected first-half 2026), RASolute 303 (daraxonrasib ± chemotherapy in first-line PDAC), RASolute 304 (daraxonrasib adjuvant in resectable PDAC), RASolute 305 (zoldonrasib plus chemotherapy in first-line PDAC), and RASolve 301 (daraxonrasib vs. docetaxel in RAS mutant NSCLC). All drug substance and drug product manufacturing is outsourced to contract development and manufacturing organizations under cGMP agreements.
Show full overview
The company's principal near-term value inflection is the RASolute 302 readout in second-line PDAC, anticipated in the first half of 2026. In October 2025, the FDA granted daraxonrasib both a non-transferable Commissioner's National Priority Voucher and Orphan Drug Designation for pancreatic cancer; in June 2025, daraxonrasib received Breakthrough Therapy Designation for previously treated metastatic PDAC. If RASolute 302 data do not meet pre-specified endpoints, the company's ability to raise additional capital and sustain five concurrent Phase 3 programs could be materially impaired, given that the Royalty Purchase Agreement's additional funding tranches are conditioned on commercial milestones. Adverse results could also weigh on Term Loan Facility covenants, which restrict the company's ability to incur additional liens or dispose of certain daraxonrasib-related assets.
See also: Healthcare · Biotechnology
From Revolution Medicines, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-15Recent Developments — Revolution Medicines, Inc.
Latest news
- NEWS Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $220 — benzinga Jun 10, 2026 positive
- NEWS RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $182 — benzinga Jun 2, 2026 positive
- NEWS HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $195 — benzinga Jun 1, 2026 positive
- NEWS Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $195 — benzinga Jun 1, 2026 positive
- NEWS Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time — benzinga May 31, 2026 positive
Generated 2026-06-17T09:07:23Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinedaraxonrasib (RASolute 302)10-K Item 1: 'RASolute 302: comparing daraxonrasib against chemotherapy in patients with second line (2L) PDAC; a clinical readout for this study is currently expected in the first half of 2026'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $158.96: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $148.00. Score 4.6/10, moderate confidence.
Take-profit target: $168.56 (+5.9% upside). Prior stop was $148.00. Stop-loss: $148.00.
Concentration risk — Pipeline: daraxonrasib (RASolute 302); Quality below floor (1.7 < 4.0).
Revolution Medicines, Inc. trades at a P/E of N/A (forward -27.0). TrendMatrix value score: 6.0/10. Verdict: Sell.
27 analysts cover RVMD with a consensus score of 4.4/5. Average price target: $187.
What does Revolution Medicines, Inc. do?Revolution Medicines is a clinical-stage precision oncology company developing RAS(ON) inhibitors. Lead asset...
Revolution Medicines is a clinical-stage precision oncology company developing RAS(ON) inhibitors. Lead asset daraxonrasib is in multiple Phase 3 trials for pancreatic cancer and NSCLC, with a key readout from RASolute 302 expected in H1 2026. The pipeline also includes zoldonrasib (G12D), elironrasib (G12C), and RMC-5127 (G12V).